# Combination Therapy in Cancers With Mutations in DNA Repair Genes

> **NCT05694715** · PHASE1 · RECRUITING · sponsor: **University of California, San Francisco** · enrollment: 24 (estimated)

## Conditions studied

- Metastatic Solid Tumor
- BRCA1 Mutation
- BRCA2 Mutation
- ATM Gene Mutation
- PALB2 Gene Mutation

## Interventions

- **DRUG:** Niraparib
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT05694715
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-23
- **Primary completion:** 2028-01-31
- **Final completion:** 2028-01-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05694715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05694715, "Combination Therapy in Cancers With Mutations in DNA Repair Genes". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05694715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*